Chief Medical Officer
Koneksa Health
John A. Wagner, M.D., Ph.D., oversees clinical trials and strategy at Koneksa. With more than 25 years of drug development experience, Dr. Wagner has led more than 150 first-in-human studies and has been instrumental in bringing numerous blockbuster programs to market. Prior to joining Koneksa, John was CMO of Cygnal Therapeutics (merged with Inzen in 2022 to from Sonata), held senior leadership roles at Takeda and Merck, and was a venture partner at Foresite Capital. In addition, John is editor-in-chief of Clinical and Translational Science and an executive committee member of the Foundation for the National Institutes of Health Biomarkers Consortium.
Disclosure(s): CTS: Employment (Ongoing); FNIH biomarkers consortium: Consultant/Advisory Board (Ongoing); General Atlantic: Consultant/Advisory Board (Ongoing); Koneksa Health: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Thursday, March 28, 2024
1:30 PM – 3:00 PM MDT
Fountain of Youth: Fighting Aging to Prevent Age-Related Diseases
Friday, March 29, 2024
11:00 AM – 12:00 PM MDT